NPCE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Neuropace Inc (NPCE) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has positive revenue growth trends, strong analyst support with increasing price targets, and upcoming earnings that could act as a catalyst. While technical indicators are neutral, the overall sentiment and growth potential make it a solid long-term investment.
The MACD is below 0 and negatively contracting, indicating a neutral to slightly bearish momentum. RSI is neutral at 56.519, and moving averages are converging, showing no clear trend. Key resistance is at 15.383, with support at 14.175. The pre-market price of 15.09 is near resistance, suggesting limited short-term upside.
Analysts have raised price targets recently, with UBS setting a target of $22 and H.C. Wainwright projecting $
Revenue growth of 29.89% YoY in Q3 2025 indicates strong business performance.
Gross margin improved to 77.39%, up 5.70% YoY.
Upcoming Q4 2025 earnings release on 2026-03-05 could act as a positive catalyst.
Net income dropped by -35.88% YoY, and EPS declined by -42.11% YoY, reflecting profitability challenges.
No recent significant hedge fund or insider trading activity, indicating limited institutional interest.
In Q3 2025, revenue increased by 29.89% YoY to $27.35M, showing strong growth. However, net income dropped to -$3.496M (-35.88% YoY), and EPS declined to -0.11 (-42.11% YoY). Gross margin improved to 77.39% (+5.70% YoY), indicating better cost management.
Analysts are bullish on NPCE, with multiple firms raising price targets recently. UBS set a target of $22, H.C. Wainwright raised it to $19, and JPMorgan increased it to $20, all maintaining Buy or Overweight ratings. This reflects strong confidence in the company's growth prospects.
